ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Study to Evaluate the Effect of SLV320 in Addition to Chronic Furosemide Treatment on Renal Function in Subjects With Congestive Heart Failure and Impaired Renal Function

This study has been terminated.
Study NCT00568009.   Last updated on April 18, 2008.   Information provided by Solvay Pharmaceuticals
Please refer to this study by its ClinicalTrials.gov identifier: NCT00568009


Locations
United States, California
Site 96    
      Whittier, California, United States
United States, Florida
Site 90    
      Miami, Florida, United States
Site 95    
      Largo, Florida, United States
United States, Georgia
Site 88    
      Atlanta, Georgia, United States
Site 92    
      Covington, Georgia, United States
United States, Illinois
Site 106    
      Melrose Park, Illinois, United States
United States, Maryland
Site 87    
      Hagerstown, Maryland, United States
United States, New York
Site 94    
      Springfield Gardens, New York, United States
United States, Texas
Site 89    
      Dallas, Texas, United States
Site 97    
      San Antonio, Texas, United States
Argentina
Site 11    
      Bahia Blanca, Argentina
Site 4    
      San Martin, Argentina
Site 5    
      La Plata, Argentina
Site 6    
      Coronel Suarez, Argentina
Site 102    
      Salta, Argentina
Site 2    
      Bahia Blanca, Argentina
Site 101    
      Capital Federal, Argentina
Site 8    
      Santa Fe, Argentina
Site 104    
      Mar del Plata, Argentina
Site 1    
      Corrientes, Argentina
Site 105    
      San Luis, Argentina
Belgium
Site 12    
      Huy, Belgium
Site 14    
      Antwerpen, Belgium
Site 15    
      Gent, Belgium
Czech Republic
Site 16    
      Jindrichuv Hradec, Czech Republic
Site 17    
      Semily, Czech Republic
Site 18    
      Slany, Czech Republic
Site 19    
      Kromeriz, Czech Republic
Site 20    
      Praha, Czech Republic
Site 21    
      Praha, Czech Republic
Site 22    
      Brno, Czech Republic
Site 23    
      Teplice, Czech Republic
Germany
Site 28    
      Berlin, Germany
Site 26    
      Dortmund, Germany
Site 24    
      Bad Nauheim, Germany
Poland
Site 47    
      Lublin, Poland
Site 48    
      Warszawa, Poland
Site 49    
      Plock, Poland
Site 50    
      Bydgoszcz, Poland
Site 51    
      Zielona Gora, Poland
Site 52    
      Warszawa, Poland
Site 56    
      Warszawa, Poland
Site 54    
      Torun, Poland
Site 55    
      Wroclaw, Poland
Site 53    
      Warszawa, Poland
Site 57    
      Skierniewice, Poland
Russian Federation
Site 58    
      Moscow, Russian Federation
Site 59    
      Samara, Russian Federation
Site 60    
      saint-Petersburg, Russian Federation
Site 61    
      Moscow, Russian Federation
Site 62    
      Moscow, Russian Federation
Site 63    
      Moscow, Russian Federation
Site 64    
      Moscow, Russian Federation
Serbia and Montenegro
Site 65    
      Belgrade, Serbia and Montenegro
Site 66    
      Belgrade, Serbia and Montenegro
Site 69    
      Belgrade, Serbia and Montenegro
Site 70    
      Zemun, Serbia and Montenegro
Site 68    
      Niska Banja, Serbia and Montenegro
Site 67    
      Sremska Kamenica, Serbia and Montenegro
South Africa
Site 74    
      Worcester, South Africa
Site 71    
      Somerset West, South Africa
Site 73    
      Kempton Park, South Africa
Site 72    
      Belville, South Africa
Site 76    
      Bloemfontein, South Africa
Site 75    
      Belville, South Africa
Site 98    
      Durban, South Africa
Spain
Site 83    
      Barcelona, Spain
Site 79    
      Madrid, Spain
Site 77    
      Malaga, Spain
Site 82    
      Santander, Spain
Site 78    
      Barcelona, Spain
Site 80    
      Valencia, Spain

Sponsors and Collaborators
Solvay Pharmaceuticals
Quintiles

Investigators
Study Director:     Global Clinical Director Solvay     Solvay Pharmaceuticals    





Links to all studies - primarily for crawlers